Although different strategies have been explored to overcome the primary resistance of wt-EGFR to TKIs [12–14], there is still a need to develop other strategies dedicated to different sensitization mechanisms, which may improve the understanding of resistance and provide therapeutic regimens that could maximize the therapeutic efficacy of EGFR-TKIs in wt-EGFR lung cancer. This evidence concerns the gene EGFR and lung cancer.